The clinical relevance of our findings is underscored by the abundant expression of both YAP1 and TGFβ downstream target genes within the TME of the LAPC9 PDX model, the aggressive PRN prostate GEMM model and aggressive/resistant disease stages of clinical PCa. The gene discussed is YAP1; the disease is posterior cortical atrophy.